Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck.

@article{Linares2016EmergenceOL,
  title={Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck.},
  author={J. I. Vico Linares and Antonio J Rull{\'a}n and Miren Taberna and Silvia V{\'a}zquez and Ricard Mes{\'i}a},
  journal={Oral oncology},
  year={2016},
  volume={55},
  pages={
          e4
        }
}
http://dx.doi.org/10.1016/j.oraloncology.2016.02.006 1368-8375/ 2016 Elsevier Ltd. All rights reserved. Approximately 30% of all patients diagnosed with Squamous Cell Carcinoma of the Head and Neck (SCCHN) will ultimately have recurrent disease or distant metastasis that render them unable to receive radical treatment. Systemic palliative therapy is then the treatment of choice, achieving a median overall survival of 10 months with the combination of chemotherapy (CT) and Cetuximab [1]. From… CONTINUE READING